Lifecore Biomedical Signs Tech Transfer Agreement for Ophthalmic

Lifecore Biomedical, Inc., a CDMO, has signed a manufacturing services agreement with a leading provider of ophthalmic disease management solutions. Under the terms of the agreement, Lifecore will perform process development and technical transfer services in support of anticipated commercial manufacturing upon regulatory approval.

“We are pleased to announce another customer win and the opportunity to support an important new technical transfer program,” said Paul Josephs, chief executive officer of Lifecore. “This agreement reflects Lifecore’s recognized, technical expertise and specialized manufacturing capabilities in the ophthalmic injectables space.

“This program, which involves transitioning a next-generation reformulation of the commercially approved product from vials to pre-filled syringes, represents a fast-growing modality which is core to our capabilities. This new program further strengthens our growing, late-stage portfolio and builds additional momentum behind our broader strategy to drive sustainable long-term growth. As we continue to add new programs to Lifecore, our team remains focused on delivering strong execution, maintaining the high-quality standards, and serving as a trusted partner in bringing needed therapies to market.”